Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00869232 · ClinicalTrials.gov registry record · Phase 2

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

A Phase 2 study of Multiple Myeloma, sponsored by University of Arkansas.

Active
Registry status
Phase 2
Development phase
90
Enrollment target
1
Study location

NCT00869232 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by University of Arkansas. The registered enrollment target is 90 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00869232, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by University of Arkansas.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have lived longer and had better responses to treatment) when compared to individuals treated with standard chemotherapy. Past studies conducted at the MIRT and at other institutions have shown that participants with high-risk features by gene array studies tend to have shorter remissions (disappearance of signs and symptoms of myeloma) and do not survive as long as participants with low-risk myeloma. Researchers at MIRT think that one reason for this is that the myeloma cells re-grow in the time when participants are not receiving treatment because they are recovering from high-dose chemotherapy. In this study, participants will receive several chemotherapy drugs previously shown to be effective in myeloma, but in lower doses and in shorter cycles. It is hoped that by giving the drugs in this way, myeloma cells will not have time to re-grow between cycles, therefore resulting in longer remissions. This study is being done in an attempt to improve the remission rate and the survival time for participants with high-risk myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Melphalan
  • DRUG Cisplatin
  • DRUG Dexamethasone
  • DRUG Thalidomide
  • DRUG Velcade

Study Locations (1)

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2008-10
Est. Completion 2027-10
Phase Phase 2

Sponsor

University of Arkansas

318 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00869232

The ClinicalTrials.gov registry entry for NCT00869232 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% lower). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.

NCT00869232 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.

Frequently Asked Questions

What is clinical trial NCT00869232 about?

NCT00869232 is a clinical study titled "UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission". There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have lived longer and had better responses to treatment) when compared to indi...

What is the current status of trial NCT00869232?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2008-10. Estimated completion is 2027-10.

What conditions does trial NCT00869232 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT00869232?

The interventions under investigation include: Melphalan (DRUG), Cisplatin (DRUG), Dexamethasone (DRUG), Thalidomide (DRUG), Velcade (DRUG).

Who is sponsoring clinical trial NCT00869232?

This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00869232 being conducted?

This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.